Debra Miller

Newport Beach, California, United States Contact Info
682 followers 500+ connections

Join to view profile

About

Debra Miller is Chief Executive Officer and Founder of CureDuchenne, a non-profit…

Activity

Join now to see all activity

Experience & Education

  • CureDuchenne

View Debra’s full experience

By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.

Volunteer Experience

  • Board Observer

    Code Bio Therapeutics, Inc.

    - Present 3 years

    Science and Technology

    Code Bio is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases.

  • Patient Representative

    TREAT-NMD Executive Committee

    - Present 3 years

    Health

    The TREAT-NMD Executive Committee is made up of nine academic representatives and four patient representatives. The Executive Committee is responsible for providing overall policy and strategic direction to the TREAT-NMD Alliance, oversees activities and progress, and delegates responsibility for day-to-day operations to the representatives of the various activity groups.

  • PepGen Graphic

    Board Observer

    PepGen

    - Present 3 years

    Science and Technology

    PepGen, Inc. is a biotechnology company advancing next-generation oligonucleotide therapies for neuromuscular diseases. PepGen’s proprietary Enhanced Delivery Oligonucleotides (EDOs) are designed to safely and effectively target the underlying causes of rare genetic diseases such as Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).

  • Member Board Of Directors

    Exonics Therapeutics

    - 2 years

    Exonics Therapeutics is a biotechnology company focusing on utilizing gene editing technologies like CRISPR/Cas9 to advance the development of a treatment for Duchenne muscular dystrophy.

  • Committee Member

    TREAT-NMD TACT Review Committee

    - 3 years

    Health

    The TREAT-NMD Advisory Committee for Therapeutics (TACT) is a unique multi-disciplinary international group of internationally recognized academic and industry drug development experts as well as representatives of patient foundations and regulatory experts, who meet twice a year to review and provide guidance on the translation and development path of therapeutics programs in rare neuromuscular diseases with large unmet need.

Honors & Awards

  • Coast Magazine Woman of the Year Honoree

    Coast Magazine

  • Luminary Award from Texas Healthcare & Bioscience Institute (THBI)

    Texas Healthcare & Bioscience Institute (THBI)

    The annual Luminary Awards honor individuals for their contributions and efforts to further the development of the life science industry in Texas.

  • Rare Impact Awards Honoree

    National Organization for Rare Disorders (NORD®)

    Outstanding individuals, organizations and industry innovators honored for their exceptional work benefiting the rare disease community.

  • OCBJ Women in Business Award

    Orange County Business Journal

    The Orange County Business Journal awards recognize clients, colleagues, and friends whose Orange-County-based firms have distinguished themselves via their business accomplishments and contributions to the local community.

  • EY Entrepreneur of the Year™ Award in Orange County

    Ernst & Young LLP

    Entrepreneur Of The Year Award winners become lifetime members of a global, multi-industry community of entrepreneurs, with exclusive, ongoing access to the experience, insight and wisdom of program alumni and other ecosystem members in over 60 countries — all supported by vast EY resources. Since 1986, the Entrepreneur Of The Year program has recognized more than 10,000 US executives.

Organizations

  • Alliance for Regenerative Medicine

    Board Member

    - Present

    The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. As the global voice of the sector, ARM represents the interests of 400+ members across 25 countries, including small and large companies, academic research institutions, major medical centers and patient groups.

  • Bespoke Gene Therapy Consortium

    Consortium Partner

    - Present

    The Accelerating Medicines Partnership® (AMP®) program is a public-private partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and multiple public and private organizations, including CureDuchenne. The AMP Bespoke Gene Therapy Consortium (BGTC) aims to develop platforms and standards that will speed the development and delivery of customized or “bespoke” gene therapies that could treat the millions of people affected by rare diseases.

  • Muscular Dystrophy Coordinating Committee (MDCC)

    Committee Member

    - Present

    A Federal Advisory Committee that coordinates the activities across the National Institutes and with other Federal health programs and activities relating to the various forms of muscular dystrophy.

  • Department of Defense’s Congressionally Directed Medical Research Committee Programmatic Panel

    TREAT-NMD - TACT Review Committee Member

    - Present

    The office of the Congressionally Directed Medical Research Programs (CDMRP) manages Congressional Special Interest Medical Research Programs (CSI) encompassing breast, prostate, and ovarian cancers, neurofibromatosis, military health, and other specified areas.

More activity by Debra

View Debra’s full profile

  • See who you know in common
  • Get introduced
  • Contact Debra directly
Join to view full profile

People also viewed

Explore collaborative articles

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Explore More

Others named Debra Miller in United States

Add new skills with these courses